Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
1. Stifel initiated coverage on Avalo Therapeutics, rating it as Buy. 2. AVTX-009 is targeting hidradenitis suppurativa with Phase 2 trials underway. 3. Topline data for AVTX-009 is expected by 2026. 4. Stifel anticipates strong potential in HS market with over $2 billion revenue. 5. Avalo's current cash is sufficient to fund operations into 2027.